Percutaneous edge-to-edge mitral valve repair with the MitraclipTM device has been an FDA-approved therapy for primary mitral regurgitation in patients with prohibitive surgical risk since 2013, but after the recent publication of the COAPT trial these indications were vastly expanded to include patients with secondary mitral regurgitation and heart failure. This fact, as well as other devices in the horizon will significantly expand the number of patients who are candidates for percutaneous valve repair and who will present to echocardiography laboratories for specialized imaging. It is thus important for clinicians, echocardiographers, cardiac anesthesiologists and interventional cardiologist to understand the echocardiographic parameters for optimal patient selection, preprocedural evaluation and planning, intraprocedural guidance and postprocedural evaluation of patients with mitral regurgitation undergoing percutaneous valve repair.
This activity is designed for all cardiac sonographers and cardiovascular physicians with a primary interest and knowledge base in the field of echocardiography; in addition, residents, researchers, clinicians, intensivists, and other medical professionals.
Learning Objectives: At the end of this webinar the viewer will better be able to:
Describe the steps for the comprehensive echocardiographic assessment and quantification of mitral regurgitation.
Summarize the key echocardiographic criteria for optimal patient selection for percutaneous mitral valve repair.
Understand the role of real-time two- and three-dimensional TEE in the intraprocedural guidance for percutaneous mitral valve repair.
Appreciate the parameters for post-procedural assessment after percutaneous mitral valve repair and assessment of residual mitral regurgitation, and differences with native valve regurgitation.